114 filings
Page 5 of 6
6-K
29sdu70gll0
14 Jul 22
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial
11:03am
6-K
hwnrq
7 Jul 22
Current report (foreign)
7:00am
6-K
refxx 3ewl7
30 Jun 22
Notice of Annual & Special Meeting of Shareholders
6:00am
6-K
9r85igm9 8to8gzh
29 Jun 22
Current report (foreign)
9:58pm
6-K
gi7bzb1bfsz7d0lb
21 Jun 22
XORTX Announces “Fireside Chat” with XORTX CEO
7:52pm
6-K
5fqezw30rr7e6vxd
13 Jun 22
XORTX to Present at BIO International Convention 2022
9:26am
6-K
majpg mzuwcf
8 Jun 22
XORTX to Present at LD Micro Invitational 2022
7:00am
6-K
w49h1dez7xl7 y7
6 Jun 22
XORTX Welcomes New Member to the Board of Directors and Appoints Chair
7:00am
6-K
iaohed173mdlh
25 May 22
XORTX to Present at H. C. Wainwright Global Investment Conference 2022
8:00am
6-K
f4xiwze6n
16 May 22
Condensed Interim Consolidated Financial Statements
7:25am
6-K
7ixd1imweh 8zoditq
5 May 22
Current report (foreign)
7:00am
6-K
glfd 9yvt1ch
3 May 22
XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial
7:03am
6-K
nhxii9e
20 Apr 22
XORTX Receives Small and Medium Enterprise Status for the European Union
7:45am
6-K
g4qbabi2k o19fvs2
13 Apr 22
Current report (foreign)
7:23am
6-K
xi6ru97v
13 Apr 22
Consolidated Financial Statements
7:22am
6-K
91trq8 mjq
12 Apr 22
XORTX Receives No Objection Letter from Health Canada
9:57am
6-K
2sq5bab6
7 Apr 22
XORTX Announces Grant of US Patent
7:00am
6-K
1un8evpjxwo4xy6f6
31 Mar 22
Current report (foreign)
7:00am
6-K
sttzcdyzy mn28
23 Mar 22
XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
7:00am
6-K
r7gy e7keo6ga2dq9
14 Mar 22
XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study
7:00am